- Home
- ANAB vs CCEC Comparison
ANAB vs CCEC Comparison
Compare ANAB & CCEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | CCEC |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANAB | CCEC |
|---|---|---|
| Price | $51.10 | $22.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $71.67 | $23.67 |
| AVG Volume (30 Days) | ★ 542.3K | 11.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.75% |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $19.82 |
| Revenue Next Year | $52.14 | $39.95 |
| P/E Ratio | ★ N/A | $4.82 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $16.77 |
| 52 Week High | $73.30 | $24.83 |
Technical Indicators
Market Signals| Indicator | ANAB | CCEC |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 55.25 |
| Support Level | $43.75 | $19.63 |
| Resistance Level | $51.67 | $23.53 |
| Average True Range (ATR) | 2.68 | 1.09 |
| MACD | -0.99 | 0.06 |
| Stochastic Oscillator | 5.47 | 59.48 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.